clinical trial · NCT03019536
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
Eli Lilly and Company·phase1·completed·n = 22
Alzheimer DiseaseLY3303560 - IVPlacebo - IVFlorbetapir F 18Flortaucipir F18
brief summary
The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in the body. This study will last up to 65 weeks, not including screening. Screening is required within 90 days prior to the start of the study.
started
Jan 31, 2017
primary completion
Jun 5, 2019
completion
Jun 5, 2019
last updated
Oct 10, 2023
official title
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol